Allos Therapeutics, Inc. Reports New Analyses of FOLOTYN(R) Data from PROPEL Trial in Relapsed or Refractory Peripheral T-Cell Lymphoma

ORLANDO, Fla. & WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ: ALTH) today reported new analyses of data from the Company’s pivotal PROPEL trial of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) at the 52nd American Society of Hematology (ASH) Annual Meeting held in Orlando, Florida.